Citigroup
STLN

Citigroup’s Starling Oncology STLN Stock Holding History

Citigroup’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
35,747
+31,565
+755% +$133K ﹤0.01% 4359
2026
Q1 		$12.8K Buy
4,182
+2,431
+139% +$7.45K ﹤0.01% 4951
2025
Q4 		$6.23K Sell
1,751
-799
-31% -$2.96K ﹤0.01% 5183
2025
Q3 		$8.9K Sell
2,550
-18,410
-88% -$63.1K ﹤0.01% 5060
2025
Q2 		$43K Buy
20,960
+20,957
+698,567% +$52.4K ﹤0.01% 4847
2025
Q1 		$3 Sell
3
-631
-100% -$489 ﹤0.01% 5513
2024
Q4 		$196 Buy
634
+609
+2,436% +$158 ﹤0.01% 5666
2024
Q3 		$8 Sell
25
-15
-38% -$6 ﹤0.01% 5628
2024
Q2 		$18 Sell
40
-12,814
-100% -$10.9K ﹤0.01% 5497
2024
Q1 		$20.3K Buy
12,854
+12,356
+2,481% +$23.5K ﹤0.01% 5027
2023
Q4 		$1.02K Hold
498
– – ﹤0.01% 5465
2023
Q3 		$697 Hold
498
– – ﹤0.01% 5157
2023
Q2 		$274 Buy
+498
New +$263 ﹤0.01% 5415
2023
Q1 		– Sell
-235
Closed -$388 – 5860
2022
Q4 		$388 Sell
235
-294
-56% -$825 ﹤0.01% 5537
2022
Q3 		$2K Sell
529
-608
-53% -$3.58K ﹤0.01% 5537
2022
Q2 		$6K Buy
+1,137
New +$8.28K ﹤0.01% 5569

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup's STLN Position: Q2 2026 in Review

Citigroup increased its Starling Oncology (STLN) stake by 755% in Q2 2026, buying an estimated $133K and bringing the position to 35,747 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #4359.

Citigroup first reported a position in STLN in Q2 2022 and has held it in 16 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Citigroup held 35,747 shares of Starling Oncology worth $194K as of Q2 2026.
  • Citigroup bought 31,565 Starling Oncology shares in Q2 2026, an estimated $133K.
  • Starling Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4359 holding.
  • Citigroup first reported a position in Starling Oncology in Q2 2022 and has held it in 16 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.